Nolvadex tamoxifen

NOLVADEX is effective in the treatment of metastatic breast cancer in women and men. In premenopausal women with metastatic breast cancer, NOLVADEX is an alternative to oophorectomy or ovarian irradiation. Available evidence indicated that patients whose tumors are estrogen receptor positive arc more likely to benefit from NOLVADEX therapy. Adjuvant Treatment of Breast Cancer: NOLVADEX is indicated for the treatment of node-positive breast cancer in postmenopausal women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. NOLVADEX is also indicated for the treatment of axillary node-negative breast cancer in women following total mastectomy or segmental mastectomy, axillary dissection, and breast irradiation. In addition, NOLVADEX reduces the occurrence of contra lateral breast cancer in patients receiving adjuvant therapy with NOLVADEX for breast cancer. Ductal Carcinoma in Situ (DCIS): In women with DCIS, following breast surgery and radiation, NOLVADEX is indicated to reduce the risk of invasive breast cancer. (See BOXED WARNING at the beginning of full prescribing information.) Reduction in Breast Cancer Incidence in High-Risk Women: NOLVADEX is indicated to reduce the incidence of breast cancer in women at high risk for breast cancer. NOLVADEX is indicated only for high-risk women. “High risk” is defined as women at least 35 years of age with a 5-year predicted risk of breast cancer a 1.67%, as calculated by the Gail Model. (See Full prescribing information.)

Leave a Reply